Patent · US Active

RNAs for complement inhibition

US11510939B1 · kind B1 · utility

1Cited by

1References

16Claims

0Family size

Assignee

Apellis Pharmaceuticals, Inc. · US

Inventors

Christian Mueller · Wiesbaden, DE
Lukas Scheibler · Laguna Beach, US

Key dates

Filing date	Apr 20, 2020
Grant date	Nov 29, 2022
Priority date	—
Expiry date	Apr 20, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2750/14145
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

RNAs, such as miRNA and siRNA, and their use in treating complement-mediated disorders, are described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.